Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Roche presents novel pyrrolodine aryl-ether compounds

March 24, 2009

Exalgo extended-release meets primary efficacy endpoint in phase III trial

March 24, 2009

FDA approves Symbyax for treatment-resistant depression

March 24, 2009

Novel histamine H3 receptor antagonist presented by Pfizer

March 24, 2009

FDA approves Lexapro for major depressive disorder in adolescents

March 24, 2009

Shire voluntarily recalls Daytrana transdermal patch due to release liner defect

March 24, 2009

Tapentadol extended release shows efficacy and safety in phase III study of chronic pain

March 24, 2009

GW-3965 improves cognition in impaired mice

March 24, 2009

Characteristics of gamma-secretase inhibitor BMS-708163 detailed

March 23, 2009

Novel cannabinoid 2 receptor agonists reported by Merck & Co.

March 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...